BACKGROUND: The optimal graft-versus-host disease (GVHD) prophylaxis after umbilical cord blood transplantation has not been established. Our previous observation using single calcineurin inhibitors revealed a high incidence and severity of early immune-mediated complications, especially for older patients or those with poor performance status. METHODS: We conducted a single institute pilot study assessing the safety and effectiveness of mycophenolate mofetil (MMF) and tacrolimus (FK) combination as a GVHD prophylaxis for 29 patients (FK+MMF), and the results were compared with matched-pairs extracted from our historical database who received FK alone as GVHD prophylaxis (control). RESULTS: FK+MMF group showed superior engraftment rate compared with control group (cumulative incidence until day 60 posttransplant; 90%±0% vs. 69%±1%, P=0.02). A cumulative incidence of severe type preengraftment immune reactions was significantly decreased in FK+MMF group (16%±1%) compared with that of control group (52%±2%, P=0.03), and, remarkably, there was no nonrelapse mortality (NRM) observed up to day 30 posttransplant in FK+MMF group, whereas 21%±1% of NRM was observed in the control group. However, the incidences of acute and chronic GVHD, estimated overall and progression-free survivals were comparable between two groups. CONCLUSIONS: MMF and FK in combination was well tolerated and decreased early NRM possibly by better control of preengraftment immune reactions. Subsequent NRM or disease progression needs to be overcome to further improve survival.
BACKGROUND: The optimal graft-versus-host disease (GVHD) prophylaxis after umbilical cord blood transplantation has not been established. Our previous observation using single calcineurin inhibitors revealed a high incidence and severity of early immune-mediated complications, especially for older patients or those with poor performance status. METHODS: We conducted a single institute pilot study assessing the safety and effectiveness of mycophenolate mofetil (MMF) and tacrolimus (FK) combination as a GVHD prophylaxis for 29 patients (FK+MMF), and the results were compared with matched-pairs extracted from our historical database who received FK alone as GVHD prophylaxis (control). RESULTS:FK+MMF group showed superior engraftment rate compared with control group (cumulative incidence until day 60 posttransplant; 90%±0% vs. 69%±1%, P=0.02). A cumulative incidence of severe type preengraftment immune reactions was significantly decreased in FK+MMF group (16%±1%) compared with that of control group (52%±2%, P=0.03), and, remarkably, there was no nonrelapse mortality (NRM) observed up to day 30 posttransplant in FK+MMF group, whereas 21%±1% of NRM was observed in the control group. However, the incidences of acute and chronic GVHD, estimated overall and progression-free survivals were comparable between two groups. CONCLUSIONS:MMF and FK in combination was well tolerated and decreased early NRM possibly by better control of preengraftment immune reactions. Subsequent NRM or disease progression needs to be overcome to further improve survival.
Authors: Y Arai; T Kondo; T Kitano; M Hishizawa; K Yamashita; N Kadowaki; T Yamamoto; I Yano; K Matsubara; A Takaori-Kondo Journal: Bone Marrow Transplant Date: 2014-11-10 Impact factor: 5.483
Authors: M Ogata; K Oshima; T Ikebe; K Takano; H Kanamori; T Kondo; Y Ueda; T Mori; H Hashimoto; H Ogawa; T Eto; T Ueki; T Miyamoto; T Ichinohe; Y Atsuta; T Fukuda Journal: Bone Marrow Transplant Date: 2017-08-07 Impact factor: 5.483
Authors: J Kanda; L Kaynar; Y Kanda; V K Prasad; S H Parikh; L Lan; T Shen; D A Rizzieri; G D Long; K M Sullivan; C Gasparetto; J P Chute; A Morris; S Winkel; J McPherson; J Kurtzberg; N J Chao; M E Horwitz Journal: Bone Marrow Transplant Date: 2013-01-21 Impact factor: 5.483